23 Sep 2018 | 5:08 AM
Research Report

Equity Research Report: Master Pick-Cadila Healthcare

Cadila Healthcare is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. Cadila's product pipeline for the US remains decent with 260 filings and 99 approvals. The company expects the pace of ANDA approval to pick up (15-20 in FY16) as several facilities have been cleared by the USFDA.
21 Aug 2015 | 05:00 PM

At current juncture, Cadila Healthcare is sustaining above past thee month trading range (1600-1900). This is a positive development indicting strength. Considering all, we believe it will continue to outperform. Short term investors can accumulate it in range 1850-1900 keeping close below stop loss at 1780 for the target of 2200.